Dr. Clay Siegall is a scientist and a leading biotechnology researcher who has made major contributions in cancer research. Dr. Siegall is a scientist by training, and he has played a significant role in the growth of several biotechnology companies. Additionally, he has also supervised the development of antibody-drug conjugates.
Dr. Siegall is zoologist by training from the University of Maryland. He obtained his Ph.D. in genetics at The George Washington University. His background as a scientist has made him passionate. This unwavering passion has led to his contributions towards the development of various cancer therapies. Dr. Siegall is the current President of Seattle Genetics, a company he officially unveiled in 1998. As the CEO, Dr. Siegall has built the company to its current position of greatness. Among his notable achievements, include the licensing of the company’s antibody- drug conjugates technology.
Through his leadership, Seattle Genetics has developed various drugs for the treatment of several types of cancers. These drugs include Adcetris that treats Hodgkin Lymphoma and 33A that treats myeloid leukemia. Adcetris is a commercialized drug that has fetched the company hundreds of millions of dollars. Seattle Genetics is on the verge of releasing twelve more drugs to fight various forms of cancers. Seattle Genetics is in the process of recruiting more employees by the end of 2016.
Dr. Siegall’s previous work experience and achievements
Prior to establishing Seattle Genetics, Dr. Siegall worked at the National Institute of Health and Cancer from 1988 to 1991. In 1991, he got a job at Bristol-Myers Squibb Pharmaceutical Research Institute where he served as a principal scientist. He currently serves as an external director of the board of directors of several biotechnology companies such as Alder Biopharmaceutical Inc., Mirna Therapeutics Inc., and Ultragenyx Pharmaceutical.
Dr. Siegall has received various high-status awards. In 2012, Dr. Siegall won the Entrepreneur of the Year Award by Pacific Northwest Ernst. In 2013, the University of Maryland named him the Alumnus of the Year for computer, math, and natural sciences. Currently, his objective is to turn Seattle Genetics to a leading developer of effective cancer treatment therapies.